| Primary | Percentage of Participants With Solicited Local Adverse Events (AEs) Post First Vaccination | Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination. | The full analysis set (FAS) included all participants who were randomized and who received at least one dose of study vaccine. | Posted | | Number | | percentage of participants | | 7 days after first vaccination on Day 1 (Day 8) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. | | OG002 | Placebo | Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00070.9
- OG00178.2
- OG00227.3
|
|
| |
| Primary | Percentage of Participants With Solicited Local AEs Post Second Vaccination | Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 7 days after second vaccination on Day 85 (Day 92) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. |
|
| Primary | Percentage of Participants With Solicited Local AEs Post Third Vaccination | Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 7 days after third vaccination on Day 169 (Day 176) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. |
|
| Primary | Percentage of Participants With Solicited Local AEs Post Fourth Vaccination | Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 7 days after fourth vaccination on Day 337 (Day 344) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. |
|
| Primary | Percentage of Participants With Solicited Systemic AEs Post First Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination. | FAS included all participants who were randomized and who received at least one dose of study vaccine. | Posted | | Number | | percentage of participants | | 7 days after first vaccination on Day 1 (Day 8) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. |
|
| Primary | Percentage of Participants With Solicited Systemic AEs Post Second Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination. | FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 7 days after second vaccination on Day 85 (Day 92) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine |
|
| Primary | Percentage of Participants With Solicited Systemic AEs Post Third Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination. | FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 7 days after third vaccination on Day 169 (Day 176) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine |
|
| Primary | Percentage of Participants With Solicited Systemic AEs Post Fourth Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination. | FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 7 days after fourth vaccination on Day 337 (Day 344) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine |
|
| Primary | Percentage of Participants With Unsolicited AEs for 28 Days After First Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as "solicited AEs" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. | Posted | | Number | | percentage of participants | | 28 days after first vaccination on Day 1 (Day 29) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | |
|
| Primary | Percentage of Participants With Unsolicited AEs for 28 Days After Second Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as "solicited AEs" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 28 days after second vaccination on Day 85 (Day 113) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 |
|
| Primary | Percentage of Participants With Unsolicited AEs for 28 Days After Third Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as "solicited AEs" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 28 days after third vaccination on Day 169 (Day 197) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 |
|
| Primary | Percentage of Participants With Unsolicited AEs for 28 Days After Fourth Vaccination | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as "solicited AEs" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | | Number | | percentage of participants | | 28 days after fourth vaccination on Day 334 (Day 362) | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 |
|
| Primary | Percentage of Participants With Discontinuations From Vaccination Due to AEs | Percentage of participants with discontinuations from vaccination due to AEs were reported. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. | Posted | | Number | | percentage of participants | | Up to Week 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. |
|
| Primary | Percentage of Participants With Serious Adverse Events (SAEs) During Main Study | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. | Posted | | Number | | percentage of participants | | Up to Week 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 |
|
| Primary | Percentage of Participants With SAEs During Long Term Extension (LTE) Period | An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above. This outcome measure was planned to be analyzed for specified arm only. | The FAS included all participants those were all the participants from the Tetravalent Ad26.Mos4.HIV group who had received all 4 vaccinations and were negative for HIV infections at Week 72. | Posted | | Number | | percentage of participants | | From Week 96 to Week 264 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Primary | Percentage of Participants With AEs of Special Interest During Main Study | Percentage of participants with AEs of special interest during main study were reported. HIV infection was considered as an AE of special interest. | The FAS included all participants who were randomized and who received at least one dose of study vaccine. | Posted | | Number | | percentage of participants | | Up to Week 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. |
|
| Primary | Percentage of Participants With AEs of Special Interest During LTE Period | Percentage of participants with AEs of special interest during LTE period were reported. HIV infection was considered as an AE of special interest. This outcome measure was planned to be analyzed for specified arm only. | The FAS included all participants those were all the participants from the Tetravalent Ad26.Mos4.HIV group who had received all 4 vaccinations and were negative for HIV infections at Week 72. | Posted | | Number | | percentage of participants | | From Week 96 to Week 264 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
| |
| Primary | Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 28 | Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 28 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (>) lower limit of quantification (LLOQ) if baseline value less than (<) LLOQ or missing or defined as post-baseline value >3-fold increase from baseline if baseline value greater than or equal to (>=) LLOQ. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories. | Posted | | Number | 95% Confidence Interval | percentage of responders | | Week 28 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Primary | Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 52 | Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 52 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (>) lower limit of quantification (LLOQ) if baseline value less than (<) LLOQ or missing or defined as post-baseline value >3-fold increase from baseline if baseline value greater than or equal to (>=) LLOQ. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories. | Posted | | Number | 95% Confidence Interval | percentage of responders | | Week 52 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Primary | Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 72 | Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 72 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (>) lower limit of quantification (LLOQ) if baseline value less than (<) LLOQ or missing or defined as post-baseline value >3-fold increase from baseline if baseline value greater than or equal to (>=) LLOQ. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories. | Posted | | Number | 95% Confidence Interval | percentage of responders | | Week 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Secondary | Percentage of Responders for Human Immunodeficiency Virus Neutralizing Antibody (HIV nAb) | The functionality of vaccine-induced antibody responses was investigated by the determination of nAb activity in a virus neutralization assay (VNA) using TZM-bl cells and Env-pseudotyped viruses. The response was defined as post-baseline value >LLOQ. The LLOQ for this assay was an inhibitory concentration (IC50) of 20 (fold-dilution). The data was collected for the responses against Tier 1 HIV strain Clade C (MW965.26 and C97ZA.012). | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories. | Posted | | Number | 95% Confidence Interval | percentage of responders | | Weeks 28, 52 and 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Secondary | Percentage of Responders for Env Antibody-dependent Cellular Phagocytosis (ADCP) gp Antibody | The functionality of vaccine-induced antibody responses was investigated by the determination of ADCP. The response was defined as post-baseline value > limit of detection (LOD) if baseline value <LOD or missing or defined as post-baseline value >3-fold increase from baseline if baseline value >=LOD. The lower limits of detection (LODs) for this assay were 5.16, 6.43, 6.49, 4.32 and 4.28 (phagocytic score) for Clade A (92UG037.1), Clade B (1990a), Clade C (Con C), Clade C (C97ZA.012), and Mos1, respectively. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories. | Posted | | Number | 95% Confidence Interval | percentage of responders | | Weeks 28, 52 and 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Secondary | Percentage of Responders With Interferon-gamma (IFN-gamma) T Cell Responses Assessed Using Enzyme-linked Immunospot Assay (ELISpot) | Frozen peripheral blood mononuclear cell (PBMCs) were analyzed by interferon-gamma (IFN-gamma) (ELISpot). The response was defined as post-baseline value >P95 if baseline <P95 or missing or defined as post-baseline value >3-fold increase from baseline if baseline >=P95. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories. | Posted | | Number | 95% Confidence Interval | percentage of responders | | Weeks 26, 52 and 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Secondary | Percentage of Responders for Immunoglobulin G1 (IgG1) and IgG3 Gylcoprotein (gp) 140 Binding Antibody Assessed Using Clade C (C97ZA.012) Env Enzyme-linked Immunosorbent Assay (ELISA) | Vaccine-induced binding antibody IgG1 and IgG3 subclass responses were investigated using Clade C (C97ZA.012) specific ELISAs. The response was defined as post-baseline value >LLOQ if baseline <LLOQ or missing or defined as post-baseline value >3-fold increase from baseline if baseline >=LLOQ. The LLOQs for this assay were 12.3 and 12.4 for IgG1 and IgG3, respectively. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories. | Posted | | Number | 95% Confidence Interval | percentage of responders | | Weeks 28, 52 and 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). |
|
| Secondary | Percentage of Responders for CD4+ and CD8+ T-Cell Responses | Intracellular cytokine staining (ICS) was performed to examine the type of T-cell responding to vaccination. Responder definition was based on the Fisher's exact text between cytokine producing cells and non-producing cells in stimulated versus non-stimulated conditions. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable at specified categories | Posted | | Number | 95% Confidence Interval | percentage of responders | | Weeks 28, 52 and 72 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 |
|
| Secondary | Percentage of Participants With T-cell Development | As per change in planned analysis, this outcome measure was not performed since it was no longer considered relevant to interpret the immunogenicity of the vaccines. | The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. | Posted | | | | | | Up to Week 264 | | | | ID | Title | Description |
|---|
| OG000 | Tetravalent Ad26.Mos4.HIV Vaccine | Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5*10^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5*10^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264). | | OG001 | Trivalent Ad26.Mos.HIV Vaccine | Participants received Ad26.Mos4.HIV vaccine 5*10^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5*10^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. |
|